Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
IRVINE, Calif., April 29, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 19, 2017 lead plaintiff motion deadline.
If you purchased TherapeuticsMD shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food & Drug Administration identified deficiencies in its NDA for TX-004HR. Upon release of this news, TherapeuticsMD’s stock price dropped materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
